Weekly review: New peanut patch data, norovirus outbreaks, and more

News
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, January 6, to Friday, January 10, 2024), and click on each link to read and watch anything you may have missed.

Case study: Boy, aged 10 years, has painful nodules on his feet

A boy aged 10 years presented to the outpatient office with a history of painful nodules on the plantar surface of his bilateral feet 8 to 10 hours after spending time in a hot tub. He was unable to bear weight or put on socks and shoes due to his pain. The photos were taken soon after the painful and red papules appeared. The lesions affected the whole plantar aspect of both feet. Over the following 4 days, the nodules became less painful and red.

Click here for more on this case, and for the diagnosis.

Social media use and binge eating in early adolescence

Susan Carnell, PhD, associate professor in the Division of Child and Adolescent Psychiatry at Johns Hopkins University School of Medicine, and co-author of the "Concurrent and prospective associations of social media usage with binge eating symptoms in early adolescence," publication in Obesity, recently discussed the link between social media use and the development of binge eating behaviors in adolescents.

"The reason we did this study is because we were interested to understand more about the effects on social media," Carnell explained. "We were particularly interested in eating disorders because we know that there is potential for social media to impact mental health, but perhaps particularly eating disorders, because of the certain content to do with social comparison, which could lead to body dissatisfaction and disordered eating."

Click play on the video above for more.

Robert Frenk, MD: 2024 was big year for RSV prevention

Robert Frenck, MD, explained why 2024 was a big step in the right direction for RSV prevention, and emphasized the importance of vaccination against preventable diseases.

Click play on this quick video for more.

Screen time under 2 years of age and autism risk at 12 years

A recent JAMA Pediatrics study examined the potential link between early childhood screen time and autism spectrum disorder (ASD), considering socioeconomic factors. Researchers analyzed data from over 5000 children, revealing intriguing connections between screen time at age 2 and ASD diagnoses by age 12.

The findings suggest that excessive screen exposure could play a role in developmental outcomes, with socioeconomic factors adding complexity to the relationship. The study highlights the importance of early interventions and broader assessments of child development.

Click here for full study details and results.

CDC: 2024-2025 seasonal norovirus outbreaks up from previous years

The CDC has reported 495 norovirus outbreaks from August to mid-December 2024, marking a significant increase compared to previous years. Often called the "stomach bug," norovirus is the leading cause of vomiting, diarrhea, and foodborne illnesses in the U.S., with children, older adults, and immunocompromised individuals at higher risk of severe infections.

Dominated by the GII.17 strain this season, the virus is causing an early surge, potentially linked to lower population immunity. Symptoms, including nausea, stomach pain, and vomiting, typically appear within 12-48 hours of exposure.

Click here for more CDC data.

New data: Viaskin Peanut patch improves treatment benefit through 36 months

Encouraging new findings from an open-label extension (OLE) study show that the Viaskin Peanut patch (VP250) continues to improve peanut tolerance in toddlers aged 1 to 3 years after 36 months of treatment. The results build on the phase 3 EPITOPE trial, where significant improvements were observed at 12 months.

By month 36, 83.5% of participants achieved a peanut protein eliciting dose (ED) of ≥1000 mg, a substantial increase from 64.2% at month 12. Similarly, those reaching an ED of ≥2000 mg nearly doubled, highlighting the patch's long-term potential.

Want to learn more about how this fits into the FDA’s Accelerated Approval pathway? Explore the full details in the article.

Recent Videos
COVID-19 Roundtable: Considering off label therapies
COVID-19 Therapy Roundtable: Focusing on Inpatient Care | Image credit: Production Perig
Image credit: Production Perig
Tina Tan, MD
Rakesh Jain, MD, MPH
Rakesh Jain, MD, MPH
Brittany Bruggeman, MD
Octavio Ramilo
Octavio Ramilo, MD
Brittany Bruggeman, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.